Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This study will provide data on additional therapeutic benefits in administering Adalimumab
in patients with plaque psoriasis that showed an unsatisfactory response after at least 3
months of treatment with etanercept.